RJRebecca Schou Jurlander
Rebecca Schou Jurlander
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rebecca Schou Jurlander has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Inge Marie Svane
National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
2 shared publications Adam Andrzej Luczak
1 shared publication- Anders Handrup Kverneland
National Center of Cancer Immune Therapy, CCIT-DK, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
1 shared publication B. Albieri
National Center of Cancer Immune Therapy, CCIT-DK, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
1 shared publication- Christina Halgaard Ruhlmann
Department of Oncology, Odense University Hospital, Odense, Denmark
1 shared publication - Eva Ellebaek
National Center for Cancer Immune Therapy, Department of Oncology Copenhagen University Hospital – Herlev and Gentofte Herlev Denmark
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by Elsevier in European Journal of Cancer
Early discontinuation of immune checkpoint inhibitors after objective response in real-world melanoma: Clinical and economic impact
- 22 October 2026
- Published by Elsevier in European Journal of Cancer
Open AccessEarly discontinuation of immune checkpoint inhibitors after objective response in real-world melanoma: Clinical and economic impact
- Open Access
- 7 March 2026
- Published by Elsevier in Immuno-Oncology and Technology
- Vol. 30, 101587
Fresh-blood immune profiling of immune-related adverse events in real-world patients identifies organ-specific and steroid responsiveness signatures
- 7 March 2026
- Published by Elsevier in Immuno-Oncology and Technology
- Vol. 30, 101587
Open AccessFresh-blood immune profiling of immune-related adverse events in real-world patients identifies organ-specific and steroid responsiveness signatures